Solvemed Group

At Solvemed Group, we believe in challenging the status quo of neurological care. Our founders experienced first-hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digital biomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. In everything we do, we put the needs of patients and healthcare professionals first. We also happen to revolutionise drug discovery as our biomarkers enable disease-modifying drugs.

We respond to the unmet needs of neurological patients by providing reliable, accurate, early diagnostics and monitoring tools for better quality care and treatment outcomes. Our work has the potential to improve healthcare systems by optimising relevant care pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories, we work with our biopharmaceutical industry partners driving clinical trial efficiency and making first-in-class disease-modifying drugs possible.

Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, Harvard Medical School and Duke University, among other.

Solvemed Group headquartered in Europe, operates in the Artificial Intelligence (AI), Machine Learning, Medical Device sector. The company focuses on Artificial Intelligence (AI) and has secured $105.7M in funding across 24 round(s). With a team of 11-50 employees, Solvemed Group is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Seed Round - Solvemed Group, raised $3.6M. Discover more about their projects, partnerships, and impact on our platform.